Effect of GSK962040 on Oesophageal Function
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01366560|
Recruitment Status : Completed
First Posted : June 6, 2011
Last Update Posted : July 18, 2017
GSK962040 is a selective non-peptide motilin receptor agonist which is in development for the treatment of conditions associated with slow rates of gastric emptying. Single ascending doses (1 to 150 mg), and 14-days repeated doses (10 to 125 mg daily) have been investigated in two randomized, placebo-controlled trials. Results show that these doses were well tolerated with few mild to moderate adverse events (AE), and no clinically significant abnormal vital sign measurements, ECG changes or abnormal clinical laboratory findings. GSK962040 exhibited predictable PK with and without food. The mean within subject time for half a [13C]-containing meal to empty from the stomach (GE t½) decreased by 22-43% from placebo with GSK962040 50-150 mg single doses, and shortening of gastric emptying was confirmed at doses of 50 mg and above in the repeat dose study.
Several studies have shown that motilin agonists increase lower oesophageal sphincter (LOS) pressure and have various dose dependent effects on oesophageal peristaltic amplitudes and propulsive contractions in both healthy volunteers and patients with gastro-oesophageal reflux disease (GORD). The purpose of the present study is to examine the effect of GSK962040 on oesophageal function, using techniques such as high resolution oesophageal manometry, and pH/gastric transit using a wireless motility capsule.
|Condition or disease||Intervention/treatment||Phase|
|Gastrointestinal Motility||Drug: Active Drug: Placebo||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Double Blind Randomised Placebo Controlled Two Way Cross Over Study to Determine the Effect of GSK962040 on Oesophageal Function and Gastric Emptying in Healthy Male Volunteers.|
|Actual Study Start Date :||August 31, 2010|
|Actual Primary Completion Date :||October 22, 2010|
|Actual Study Completion Date :||October 22, 2010|
The subjects will be administered GSK962040 125 mg tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
Placebo Comparator: Placebo
The subjects will be administered placebo tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
- Change from baseline lower oesophageal sphincter (LOS) pressure (including pre and post prandial measures [ Time Frame: Baseline and at 1hr30 and 2hr15mins post dose ]
- Change from baseline oesophageal peristaltic amplitudes [ Time Frame: baseline and at 1hr30min and 2hr15mins post dose ]
- Change from baseline oesophageal peristaltic velocity. [ Time Frame: baseline and at 1hr30min and 2hr15mins post dose ]
- Change from baseline proximal gastric pressure. [ Time Frame: baseline and at 1hr30min and 2hr15mins post dose ]
- Total gastric emptying time. [ Time Frame: absolute transit time measured using SmartPill ]
- Number and proximal extent of reflux episodes [ Time Frame: 24hrs ]
- Safety and tolerability of GSK962040 [ Time Frame: baseline and at selected timepoints up to 24hrs post dose ]We will monitor ECG, vital signs, safety bloods and adverse events periodically throughout the study
- Post prandial gastric and oesophageal pH [ Time Frame: 2hr15mins post dose ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01366560
|GSK Investigational Site|
|Cambridge, United Kingdom, CB2 2GG|
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|